A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.In moving an investigational therapy from bench to bedside, drug developers have long operated within the phased development constraints of regulatory agencies such as FDA and EMA. While these constraints are […]
